All Stories

  1. Semaglutide-eye-catching results
  2. Malignant insulinoma: Can we predict the long-term outcomes?
  3. Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications
  4. NAFLD and Physical Exercise: Ready, Steady, Go!
  5. Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare
  6. Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?
  7. Minireview: are SGLT2 inhibitors heart savers in diabetes?
  8. Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies
  9. Psoriasis Severity—A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome
  10. Regional variations in definitions and rates of hypoglycaemia: findings from the global HAT observational study of 27 585 people with Type 1 and insulin-treated Type 2 diabetes mellitus
  11. The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study
  12. Male sex hormones response after a month-long Himalayas trek in relation to hemoglobin oxygen saturation
  13. Gastrin and glucoregulation in T2DM
  14. Long-Term Effectiveness of Liraglutide in Association with Patients’ Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study
  15. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
  16. Are We Compensating for the Lack of Physical Activity in Our Diabetic Patients with Treatment Intensification?
  17. Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study
  18. Impact of health policy and practice on finding the best fit for patients with type 2 diabetes after metformin failure: Croatian pilot study
  19. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study
  20. Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis
  21. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  22. The Effects of Transition from Bedtime to Morning Glargine Administration in Patients with Poorly Regulated Type 1 Diabetes Mellitus: Croatian Pilot Study
  23. New Insights into the Role of Chronic Inflammation and Cytokines in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Tumors
  24. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
  25. n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
  26. Interleukin 1β Gene Single-Nucleotide Polymorphisms and Susceptibility to Pancreatic Neuroendocrine Tumors
  27. IL-2 −330 T/G SNP and serum values—potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs)
  28. From Cellulite to smooth skin: Is Viagra the new dream cream?
  29. Glitazones and skin aging: May they stop the ticking clock?
  30. IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  31. TNF-α Promoter Single Nucleotide Polymorphisms in Gastroenteropancreatic Neuroendocrine Tumors
  32. nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma